{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:14:14Z","timestamp":1768004054580,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the past few years, there has been a continuous rise in the occurrence of renal cell carcinoma (RCC), with RCC recurrence becoming the primary factor behind fatalities. Despite numerous clinical trials, the impact of different medications on the long-term survival of patients with RCC after surgery remains uncertain. This network meta-analysis aimed to evaluate the impact of various medications on the survival and safety of drugs in individuals with RCC following nephrectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a thorough search in various databases, including CNKI, WAN FANG DATA, VIP, Web of Science, Cochrane Library (CENTRAL), PubMed, Scopus, and Embase, for articles published prior to June 2, 2023. This meta-analysis incorporated randomized controlled trials (RCTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis included 17 studies with 14,298 participants. The findings from the disease-free survival (DFS) analysis indicated that pembrolizumab demonstrated efficacy in enhancing DFS among patients with RCC following nephrectomy when compared to the placebo group (HR\u2009=\u20090.83, 95%CI 0.70 to 0.99). None of the drugs included in the study significantly improved overall survival (OS) and recurrence-free survival (RFS) after nephrectomy. For adverse events (AEs), sorafenib, pazopanib, sunitinib, and nivolumab plus ipilimumab interventions showed a higher incidence of adverse events compared with placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The network meta-analysis yielded strong evidence indicating that pembrolizumab could potentially enhance DFS in patients with RCC following nephrectomy, surpassing the effectiveness of a placebo.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-024-01441-8","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T15:03:06Z","timestamp":1709823786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Lingyu","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"1441_CR1","doi-asserted-by":"publisher","first-page":"102207","DOI":"10.1016\/j.ctrv.2021.102207","volume":"97","author":"M Larroquette","year":"2021","unstructured":"Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard JC, Ravaud A, Gross-Goupil M. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat Rev. 2021;97:102207.","journal-title":"Cancer Treat Rev"},{"key":"1441_CR2","doi-asserted-by":"publisher","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.","journal-title":"BMJ"},{"issue":"5 Suppl","key":"1441_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2005.06.112","volume":"66","author":"JS Lam","year":"2005","unstructured":"Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66(5 Suppl):1\u20139.","journal-title":"Urology"},{"issue":"1","key":"1441_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2014.04.006","volume":"67","author":"L Albiges","year":"2015","unstructured":"Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol. 2015;67(1):100\u201310.","journal-title":"Eur Urol"},{"issue":"10032","key":"1441_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"NB Haas","year":"2016","unstructured":"Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1441_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/his.13735","volume":"74","author":"B Delahunt","year":"2019","unstructured":"Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology. 2019;74(1):4\u201317.","journal-title":"Histopathology"},{"issue":"10358","key":"1441_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400(10358):1103\u201316.","journal-title":"Lancet"},{"issue":"10","key":"1441_CR8","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/annonc\/mdy329","volume":"29","author":"M Staehler","year":"2018","unstructured":"Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol. 2018;29(10):2098\u2013104.","journal-title":"Ann Oncol"},{"issue":"3","key":"1441_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.eururo.2020.12.029","volume":"79","author":"RJ Motzer","year":"2021","unstructured":"Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Lim HY, et al. Adjuvant Pazopanib Versus Placebo after Nephrectomy in patients with localized or locally Advanced Renal Cell Carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol. 2021;79(3):334\u20138.","journal-title":"Eur Urol"},{"issue":"10","key":"1441_CR10","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","volume":"108","author":"C Coppin","year":"2011","unstructured":"Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556\u201363.","journal-title":"BJU Int"},{"issue":"12","key":"1441_CR11","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","volume":"29","author":"M Gross-Goupil","year":"2018","unstructured":"Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals Oncology: Official J Eur Soc Med Oncol. 2018;29(12):2371\u20138.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"14","key":"1441_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"12","key":"1441_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"10379","key":"1441_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthelemy P, Goh JC, Ye D, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401(10379):821\u201332.","journal-title":"Lancet"},{"issue":"1","key":"1441_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2013.08.019","volume":"50","author":"M Aitchison","year":"2014","unstructured":"Aitchison M, Bray CA, Van Poppel H, Sylvester R, Graham J, Innes C, McMahon L, Vasey PA. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)\/National Cancer Research Institute trial. Eur J Cancer. 2014;50(1):70\u20137.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1441_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, et al. Adjuvant pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683\u201394.","journal-title":"N Engl J Med"},{"issue":"34","key":"1441_CR17","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1200\/JCO.20.01800","volume":"38","author":"T Eisen","year":"2020","unstructured":"Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B, et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: results from the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol. 2020;38(34):4064\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1441_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","volume":"73","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et al. Adjuvant sunitinib for high-risk renal cell Carcinoma after Nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73(1):62\u20138.","journal-title":"Eur Urol"},{"issue":"5","key":"1441_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bjc.6602443","volume":"92","author":"J Atzpodien","year":"2005","unstructured":"Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, W\u00f6ltjen HH, Jentsch H, Wieland W, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92(5):843\u20136.","journal-title":"Br J Cancer"},{"issue":"7","key":"1441_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamaoncol.2016.4419","volume":"3","author":"K Chamie","year":"2017","unstructured":"Chamie K, Donin NM, Kloepfer P, Bevan P, Fall B, Wilhelm O, Stoerkel S, Said J, Gambla M, Hawkins RE, et al. Adjuvant Weekly Girentuximab following nephrectomy for high-risk renal cell Carcinoma the ARISER Randomized Clinical Trial. Jama Oncol. 2017;3(7):913\u201320.","journal-title":"Jama Oncol"},{"issue":"6","key":"1441_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.euo.2019.08.011","volume":"2","author":"G Procopio","year":"2019","unstructured":"Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, et al. Sorafenib Versus Observation following Radical Metastasectomy for Clear-cell renal cell carcinoma: results from the phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol. 2019;2(6):699\u2013707.","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"1441_CR22","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133\u201344.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1441_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1442-2042.1997.tb00130.x","volume":"4","author":"S Naito","year":"1997","unstructured":"Naito S, Kumazawa J, Omoto T, Iguchi A, Sagiyama K, Osada Y, Hiratsuka Y. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol. 1997;4(1):8\u201312.","journal-title":"Int J Urol"},{"issue":"2","key":"1441_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/17512433.2021.1879639","volume":"14","author":"A Mennitto","year":"2021","unstructured":"Mennitto A, Verzoni E, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, et al. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Rev Clin Pharmacol. 2021;14(2):261\u20138.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"35","key":"1441_CR25","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","volume":"35","author":"RJ Motzer","year":"2017","unstructured":"Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo after Nephrectomy in patients with localized or locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916\u201323.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1441_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jamaoncol.2017.0076","volume":"3","author":"NB Haas","year":"2017","unstructured":"Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant treatment for high-risk clear cell renal Cancer: updated results of a high-risk subset of the ASSURE Randomized Trial. JAMA Oncol. 2017;3(9):1249\u201352.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1441_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00345-020-03550-z","volume":"39","author":"A Martini","year":"2021","unstructured":"Martini A, Fallara G, Pellegrino F, Cirulli GO, Larcher A, Necchi A, Montorsi F, Capitanio U. Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. World J Urol. 2021;39(5):1369\u201376.","journal-title":"World J Urol"},{"issue":"4","key":"1441_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bju.15507","volume":"129","author":"K Mori","year":"2022","unstructured":"Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2022;129(4):423\u201333.","journal-title":"BJU Int"},{"issue":"17","key":"1441_CR29","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune Checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009\u201325.","journal-title":"Curr Med Chem"},{"issue":"3","key":"1441_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.eururo.2021.03.011","volume":"80","author":"F Peyraud","year":"2021","unstructured":"Peyraud F, Larroquette M, Ravaud A, Gross-Goupil M. New insights into Adjuvant Therapy in Renal Cell Carcinoma: is the chapter of VEGF inhibitors definitely closed? Eur Urol. 2021;80(3):269\u201374.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01441-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T19:02:16Z","timestamp":1710097336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01441-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}